PDF(Pubmed)
Abstract：
BACKGROUND: In cancer chemotherapy platinum drugs do cause damage to the normal cells and as a result, many physiological functions are derailed. Renal function as measured by measured glomerular filtration rate (mGFR) plays a large role in drug dosing on the basis of the maximum tolerated dose, which is the highest dose that may be administered without unacceptable toxicity, to maximize anticancer efficacy.
OBJECTIVE: The objective of the study was to compare the toxic effect of platinum drugs on renal function as measured by mGFR in patients with malignancy and to study the difference in the magnitude of nephrotoxicity by these drugs.
METHODS: The study was conducted in the Department of Physiology in close collaboration with the Department of Radiotherapy at a tertiary care centre in Western Rajasthan, India. 150 patients suffering from different malignances undergoing treatment with cisplatin, carboplatin, and oxaliplatin were examined for their renal function as measured by mGFR using 99mTc-diethylene triamine pentaacetic acid (99mTc-DTPA) and were compared with 50 subjects of control group.
RESULTS: In the cisplatin group there was a gradual fall of GFR from 85.49 ml/min/1.73sqm to 58.09ml/min/1.73sqm at cycle II. In the carboplatin group it was 84.86ml/min/1.73sqm at baseline whereas cycle II was 75.5 ml/min/1.73sqm with SD ± 16.49. mGFR fell significantly (p<0.0001) in cisplatin and carboplatin groups but not in the cohort of patients who received oxaliplatin. The GFR reduction continued from the baseline to cycle I and then cycle II in cisplatin and carboplatin groups.
CONCLUSIONS: Nephrotoxicity is a major side effect of platin drugs and further studies should be done to establish their optimal dose in relation to renal function and minimize toxicity by trying various cytoprotective agents.
OBJECTIVE: The objective of the study was to compare the toxic effect of platinum drugs on renal function as measured by mGFR in patients with malignancy and to study the difference in the magnitude of nephrotoxicity by these drugs.
METHODS: The study was conducted in the Department of Physiology in close collaboration with the Department of Radiotherapy at a tertiary care centre in Western Rajasthan, India. 150 patients suffering from different malignances undergoing treatment with cisplatin, carboplatin, and oxaliplatin were examined for their renal function as measured by mGFR using 99mTc-diethylene triamine pentaacetic acid (99mTc-DTPA) and were compared with 50 subjects of control group.
RESULTS: In the cisplatin group there was a gradual fall of GFR from 85.49 ml/min/1.73sqm to 58.09ml/min/1.73sqm at cycle II. In the carboplatin group it was 84.86ml/min/1.73sqm at baseline whereas cycle II was 75.5 ml/min/1.73sqm with SD ± 16.49. mGFR fell significantly (p<0.0001) in cisplatin and carboplatin groups but not in the cohort of patients who received oxaliplatin. The GFR reduction continued from the baseline to cycle I and then cycle II in cisplatin and carboplatin groups.
CONCLUSIONS: Nephrotoxicity is a major side effect of platin drugs and further studies should be done to establish their optimal dose in relation to renal function and minimize toxicity by trying various cytoprotective agents.
摘要：
背景：在癌症化疗中，铂类药物确实会对正常细胞造成损害，因此，许多生理功能脱轨。根据最大耐受剂量，通过测量肾小球滤过率（mGFR）测量的肾功能在药物剂量中起着重要作用，这是可以在没有不可接受的毒性的情况下施用的最高剂量，最大限度地发挥抗癌功效。
目的：本研究的目的是比较用mGFR测定的铂类药物对恶性肿瘤患者肾功能的毒性作用，并研究这些药物的肾毒性程度的差异。
方法：该研究是在西拉贾斯坦邦的三级护理中心的生理学系与放射治疗系密切合作进行的，印度。150例患有不同恶性肿瘤的患者接受顺铂治疗，卡铂,使用99mTc-二亚乙基三胺五乙酸（99mTc-DTPA）通过mGFR检测奥沙利铂的肾功能，并与对照组的50名受试者进行比较。
结果：在顺铂组中，在周期II时，GFR从85.49ml/min/1.73sqm逐渐下降至58.09ml/min/1.73sqm。在卡铂组中,基线时为84.86ml/min/1.73sqm,而周期II为75.5ml/min/1.73sqm,SD±16.49。mGFR在顺铂和卡铂组中显著下降(p<0.0001),但在接受奥沙利铂的患者队列中没有显著下降。在顺铂和卡铂组中，GFR降低从基线持续到第I周期，然后是第II周期。
结论：肾毒性是铂类药物的主要副作用，应进一步研究确定其与肾功能相关的最佳剂量，并通过尝试各种细胞保护剂将毒性降至最低。
目的：本研究的目的是比较用mGFR测定的铂类药物对恶性肿瘤患者肾功能的毒性作用，并研究这些药物的肾毒性程度的差异。
方法：该研究是在西拉贾斯坦邦的三级护理中心的生理学系与放射治疗系密切合作进行的，印度。150例患有不同恶性肿瘤的患者接受顺铂治疗，卡铂,使用99mTc-二亚乙基三胺五乙酸（99mTc-DTPA）通过mGFR检测奥沙利铂的肾功能，并与对照组的50名受试者进行比较。
结果：在顺铂组中，在周期II时，GFR从85.49ml/min/1.73sqm逐渐下降至58.09ml/min/1.73sqm。在卡铂组中,基线时为84.86ml/min/1.73sqm,而周期II为75.5ml/min/1.73sqm,SD±16.49。mGFR在顺铂和卡铂组中显著下降(p<0.0001),但在接受奥沙利铂的患者队列中没有显著下降。在顺铂和卡铂组中，GFR降低从基线持续到第I周期，然后是第II周期。
结论：肾毒性是铂类药物的主要副作用，应进一步研究确定其与肾功能相关的最佳剂量，并通过尝试各种细胞保护剂将毒性降至最低。
